Virometix AG

Virometix Completes Enrollment in Phase I Trial of V-212 Synthetic Pneumococcal Vaccine

- Virometix AG has successfully completed enrollment of 60 healthy subjects aged 18-45 years in its Phase I clinical trial of V-212, a fully synthetic, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. - The V-212 vaccine utilizes a proprietary Synthetic Virus-Like Particle (SVLP) platform with conformational synthetic peptide mimetics designed to provide broad immunity across diverse pneumococcal serotypes, addressing limitations of current conjugate vaccines. - Preclinical studies demonstrated that V-212 prevented lethal sepsis in serotype 3 challenge models, inhibited bacterial dissemination into blood, and provided protection against serotype 8 infections in mouse and rabbit models. - The randomized, double-blind, placebo-controlled trial is being conducted in collaboration with CEVAC at Ghent University Hospital, with topline safety and immunogenicity data expected in Q1 2026.